Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06423352
PHASE1/PHASE2

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Sponsor: Alnylam Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.

Official title: A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

36

Start Date

2024-06-05

Completion Date

2025-07-17

Last Updated

2026-04-30

Healthy Volunteers

No

Interventions

DRUG

Zilebesiran

Zilebesiran administered by subcutaneous (SC) injection

DRUG

Placebo

Placebo administered by SC injection

Locations (3)

Clinical Trial Site

Fukuoka, Japan

Clinical Trial Site

Osaka, Japan

Clinical Trial Site

Tokyo, Japan